BACKGROUND: 1,5-Anhydroglucitol (1,5-AG) is inversely related to hyperglycemia and may be a useful indicator of short-term (1-2 weeks) hyperglycemia and glycemic excursions, but its prognostic value is unclear. We sought to evaluate the associations of 1,5-AG with risk of diabetes and microvascular disease.
to be an indicator of postprandial glucose excursions and short-term (1-2 weeks) hyperglycemia (8, 9 ) .
Although the assay for 1,5-AG is commercially available, there are few data linking concentrations to long-term outcomes. It is unclear if 1,5-AG is associated with microvascular complications of diabetes and if 1,5-AG adds prognostic value to Hb A 1c . We conducted this study to characterize the association of 1,5-AG with prevalent retinopathy, incident chronic kidney disease (CKD), and incident diabetes.
Methods

STUDY POPULATION
The Atherosclerosis Risk in Communities (ARIC) Study is a community-based prospective cohort of over 15 000 participants sampled from 4 US communities. The first clinic examinations (visit 1) took place from 1987 to 1989, with 3 follow-up visits approximately every 3 years (10 ) . A fifth visit was completed in 2011-2013. The second clinic examination (visit 2) took place from 1990 to 1992 and is the baseline for the present study. There were 14 348 participants who attended visit 2. Institutional review boards at each clinical site reviewed the study and informed consent was obtained from all participants.
In the present study, we excluded all persons whose race/ethnicity was recorded as other than white or black (n ϭ 42), who were fasting Ͻ8 h (n ϭ 446), or who were missing variables of interest (n ϭ 1552). Retinal photographs were not taken at baseline. Thus, for our analyses of retinopathy, we included only those participants who met our inclusion criteria and who also attended visit 3 (1993-1995) , at which time retinal photographs were taken (final analytic sample, n ϭ 9447). For analyses of incident CKD, we excluded persons with reduced kidney function, defined as an estimated glomerular filtration rate (eGFR) [calculated from serum creatinine using the 2009 CKD-Epidemiology Collaboration (CKD-EPI) equation] of Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 at baseline (final analytic sample, n ϭ 12 083). For analyses of incident diabetes, we excluded persons with diagnosed diabetes at baseline (final analytic sample, n ϭ 10 948).
MEASUREMENT OF 1,5-AG
1,5-AG (GlycoMark) was measured in 2012-2013 in stored serum samples from visit 2 (1990 -1992 ) using a Roche Modular P800 system. The interassay CV was 5%. The reliability coefficient for n ϭ 610 masked duplicate sample pairs was 0.99. Previous studies have shown this 1,5-AG assay to be reliable in long-term stored samples (11, 12 ) .
ASSESSMENT OF RETINOPATHY
Retinal photographs were taken at visit 3 (1993-1995) following a standardized protocol that has been previously described (13, 14 ) . Briefly, after 5 minutes of dark adaptation, a nonmydriatic 45-degree retinal photograph centered on the optic disc and macula was taken of 1 randomly selected eye. Trained graders masked to participant information evaluated each of the photographs. We defined any retinopathy as a severity score Ն20 according to a modification of the Airlie House classification system, as used in the modified Early Treatment Diabetic Retinopathy Study (ETDRS) (13 ) . Level 20 is commonly considered the earliest stage of diabetic retinopathy (15 ) .
ASSESSMENT OF INCIDENT CHRONIC KIDNEY DISEASE
We used the 2009 CKD-EPI creatinine equation to determine the eGFR. Among persons with normal kidney function at baseline (visit 2), we defined incident CKD as either eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 estimated from serum creatinine measured at visit 4 (1996 -1998) , accompanied by at least a 25% decrease in eGFR from baseline (visit 2), or a kidney disease hospitalization or death identified during continuous active surveillance (16 ) .
ASSESSMENT OF INCIDENT DIABETES
We identified incident (new) cases of diabetes on the basis of a self-reported diabetes diagnosis or use of diabetes medications during the ARIC visits and subsequent annual telephone calls with follow-up through April 2011. In sensitivity analyses, we evaluated 2 additional definitions of incident diabetes incorporating information on undiagnosed cases identified using glucose measurements at 2 subsequent ARIC visits (17 ) .
OTHER VARIABLES
Serum glucose was measured using the hexokinase method. Hb A 1c was measured in stored whole blood samples using HPLC with instruments standardized to the Diabetes Control and Complications Trial assay (Tosoh A 1c 2.2 Plus Glycohemoglobin Analyzer and Tosoh G7) (18 ) . Plasma lipid concentrations (19 -22 ) , body mass index (23 ) , and blood pressure (24 ) were also measured. Hypertension was defined as the mean of the second and third readings at the visit (with cutoff for systolic blood pressure of 140 mmHg or higher and/or a cutoff for diastolic blood pressure of 90 mmHg or higher) or the use of hypertension medication. Participants reported their education level, alcohol use, and smoking status. The level of physical activity was assessed with Baecke's questionnaire at visit 1 (25 ) .
STATISTICAL ANALYSES
Baseline characteristics of the study population were calculated overall and by categories of 1,5-AG at baseline. We categorized 1,5-AG according to cutpoints recommended by the manufacturer. In persons with a diagnosis of diabetes, we divided the population into 3 groups on the basis of concentrations of 1,5-AG at baseline (Ͻ6, 6 to Ͻ10, and Ն10 g/mL). In persons without a diagnosis of diabetes, we divided the population into 2 groups on the basis of concentrations of Ͻ10 and Ն10 g/mL.
Adjusted odds ratios (ORs) and their corresponding 95% CIs for retinopathy were estimated using multivariable logistic regression models. Model accuracy was assessed using the area under the ROC curve (AUC). For analyses of incident CKD and diabetes, adjusted hazard ratios (HRs) and their corresponding 95% CIs were estimated using Cox proportional hazards models. We verified that the proportional hazards assumption was met using log-log plots and by testing for risk factor-by-time interactions. To characterize the shape and assess the continuous associations of 1,5-AG with each of the clinical outcomes, we fit restricted cubic splines (26 ) . Model discrimination was assessed using Harrell's c-statistic (27 ) . To evaluate the overall improvement in risk classification for the addition of 1,5-AG to adjusted models (including models with Hb A 1c or fasting glucose), we calculated the continuous net-reclassification improvement (NRI) statistic and the integrated-discrimination-improvement (IDI) statistic (28 ) .
We constructed 4 models for each of the outcomes. Model 1 was adjusted for age, sex, race-center (5 categories: 3 categories being white participants in Minnesota, Maryland, and North Carolina; and 2 categories being black participants in North Carolina and Mississippi). Model 2 was adjusted for all variables in model 1 plus LDL cholesterol, HDL cholesterol, triglycerides, body mass index, waist-to-hip ratio, systolic blood pressure, blood pressure-lowering medication use, family history of diabetes, education level, alcohol use, smoking status, and physical activity level. Model 3 was adjusted for all variables in model 2 plus Hb A 1c . Model 4 was adjusted for all variables in model 2 plus fasting glucose. In analyses comparing categories of 1,5-AG at baseline, persons with diagnosed diabetes and 1,5-AG concentrations Ն10 g/mL served as the reference group. We tested for interactions by sex and race.
To evaluate whether 1,5-AG added prognostic information within clinically relevant categories of Hb A 1c among persons with diagnosed diabetes, we calculated the crude prevalence of retinopathy and 20-year cumulative probability (Kaplan-Meier method) of CKD by categories of 1,5-AG (Ͻ10 and Ն10 g/mL) within categories of glycemic control at baseline [Hb A 1c , Ͻ7% and Ն7% (53 mmol/mol)]. We compared the prevalence estimates using the Z-test and the 20-year probabilities using the log-rank test.
All analyses were conducted using Stata/SE version 13.0 (StataCorp).
Results
Baseline characteristics of the study population according to categories of 1,5-AG in persons with and without diagnosed diabetes are shown in Table 1 . In general, baseline risk factor associations for 1,5-AG were inverse to but highly consistent with known risk factors of diabetes and hyperglycemia. Older age, black race, higher body mass index, hypertension, lower education, higher proportion family history of diabetes, lower HDL cholesterol, and higher triglycerides were all associated with lower baseline concentrations of 1,5-AG. 1,5-AG was also strongly inversely associated with both Hb A 1c and fasting glucose, although the associations were nonlinear, with a flat association between 1,5-AG, Hb A 1c and fasting glucose at 1,5-AG concentrations Ͼ10 g/mL (see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol60/ issue11). In persons with diagnosed diabetes, the Spearman correlations with 1,5-AG were Ϫ0.84 for Hb A 1c and Ϫ0.77 for fasting glucose. Among persons without diagnosed diabetes the correlations of Hb A 1c and fasting glucose with 1,5-AG were both low (Spearman correlations of Ϫ0.08 and Ϫ0.02 for Hb A 1c and fasting glucose, respectively) (see online Supplemental Fig. 1 ). In persons with diagnosed diabetes, the 1,5-AG cut-point values of 10 g/mL and 6 g/mL represented the 64th and 50th percentiles, respectively, corresponding to fasting glucose values of approximately 165 mg/dL and 194 mg/dL (9.16 and 10.77 mmol/L) and Hb A 1c values of 7.3% and 8.2% (see online Supplemental Table 1 ). Spearman correlations between 1,5-AG and the other continuous variables were generally low regardless of diabetes status (see online Supplemental Fig. 2 ).
In the 9447 persons with retinal photographs available, there were 332 cases of retinopathy. In persons with diagnosed diabetes, low concentrations of 1,5-AG were strongly associated with retinopathy (Table 2). The lowest prevalence of retinopathy was in persons without diagnosed diabetes and 1,5-AG of Ն10 g/mL, but this association was attenuated after adjustment for major risk factors and especially after further adjustment for Hb A 1c or fasting glucose. In persons with diagnosed diabetes, those with 1,5-AG Ͻ6 g/mL were 11 times more likely to have retinopathy at visit 3 compared to persons with diagnosed diabetes and 1,5-AG of Ն10 g/mL even after adjustment (model 2, OR, 11.26; 95% CI, 6.17-20.53) ( Table 2) . These results were attenuated but remained signifi-cant after adjustment for Hb A 1c or fasting glucose (Table 2 ).
In the 12 083 persons with normal kidney function at baseline, there were 1534 incident cases of CKD during a median of 19 years of follow-up. 1,5-AG was strongly associated with incident CKD in a largely graded fashion. Persons without diagnosed diabetes and with high 1,5-AG concentrations (Ն10 g/mL) had the lowest risk of incident CKD, whereas, persons with diagnosed diabetes and 1,5-AG concentrations Ͻ6 g/mL had almost a 3-fold increased risk of CKD even after multivariable adjustment ( Table 2, Model 2: HR, 2.83; 95% CI, 2.15-3.74). After adjustment for Hb A 1c or fasting glucose, the association between lower 1,5-AG concentrations and incident CKD in persons with diabetes was attenuated but remained significant ( Table 2 , Models 3 and 4).
In the 10 948 persons without a diagnosis of diabetes at baseline, there were 2882 incident cases of diabetes during a median of 18 years of follow-up. Over this time period, persons with 1,5-AG concentrations of Ͻ10 g/mL at baseline were more than twice as likely to develop diabetes compared to persons with 1,5-AG Ն10 g/mL. The association per- Table 2 ). We did not observe statistically significant interactions by race for 1,5-AG with any of the outcomes. There were also no statistically significant interactions by sex for 1,5-AG with retinopathy or CKD. We did, however, observe a somewhat stronger association of 1,5-AG Ն10 g/mL (vs Ͻ10 g/mL) with incident diabetes in men (Model 2: HR, 3.05; 95% CI, 2.56 -3.63) compared to women (Model 2: HR, 1.83; 95% CI, 1.56 -2.15).
1,5-AG significantly improved prediction of retinopathy, CKD, and diabetes when added to a model with basic risk factors (Table 3) . When 1,5-AG was added to models already containing Hb A 1c , the improvement in the c-statistic was statistically significant for retinopathy but not incident CKD or incident diabetes. The continuous NRI and IDI statistics ), waist-to-hip ratio, mean systolic blood pressure (mmHg), blood pressure-lowering medication use (yes, no), family history of diabetes (yes, no), education (less than high school, high school or equivalent, more than high school), drinking status (current, former, never), smoking status (current, former, never), physical activity index. ] and to persons with follow-up data (n ϭ 12083). g The overall P for trend was obtained by modeling the category median (for all 5 categories) as a continuous variable. h Baseline study population was limited to persons without a history of diabetes and to persons with follow-up data (n ϭ 10948).
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for retinopathy, incident CKD, and incident diabetes showed largely similar results (see online Supplemental Table 3 ).
In the overall population (persons with and without diabetes combined), the relative association of 1,5-AG was much stronger for retinopathy compared to incident CKD, although the shapes of the associations of 1,5-AG were similar (Fig. 1) . The associations of 1,5-AG with prevalent retinopathy, incident CKD, and incident diabetes appeared strong and linear at values below approximately 15 g/mL, but there was little evidence for associations at higher values of 1,5-AG. The substantially different distributions of 1,5-AG in persons with and without diabetes are evident from the frequency histograms included in Fig. 1 . Consistent with the results presented in Table 2 , analyses of prevalent retinopathy and incident CKD stratified by diabetes status at baseline reveal that much of the association is being driven by persons with diabetes and/or low concentrations of 1,5-AG at baseline (see online Supplemental Fig. 3 ).
Among persons with a diagnosis of diabetes, the prevalence of retinopathy and absolute risk of CKD , waist-to-hip ratio, mean systolic blood pressure (mmHg), blood pressure-lowering medication use (yes, no), family history of diabetes (yes, no), education (less than high school, high school or equivalent, more than high school), drinking status (current, former, never), smoking status (current, former, never), physical activity index. Hb A 1c and 1,5-AG were modeled using restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles. Frequency histograms for 1,5-AG are shown separately for persons with diagnosed diabetes (dark grey bars) and without diagnosed diabetes (light grey bars). Adjusted ORs (for prevalent retinopathy) are from logistic regression models and adjusted HRs (for incident CKD and incident diabetes) are from Cox proportional hazards models. Baseline 1,5-AG was modeled using restricted cubic splines (solid lines) with knots at the 5th, 35th, 65th, and 95th percentiles. Models were centered at the 10th percentile of 1,5-AG. Display of the data was truncated at the 1st and 99th percentiles. The shaded areas are the 95% CIs for restricted cubic spline models. Models were adjusted for age (years), race-center, sex (male, female), LDL cholesterol (mg/dL), HDL cholesterol (mg/dL), triglycerides (mg/dL), body mass index (kg/m2), waist-to-hip ratio, mean systolic blood pressure (mmHg), blood pressure-lowering medication use (yes, no), family history of diabetes (yes, no), education (less than high school, high school or equivalent, more than high school), drinking status (current, former, never), smoking status (current, former, never), and physical activity index (score).
associated with categories of 1,5-AG (Ͻ10 and Ն10 g/mL) by categories of Hb A 1c [Ͻ7 and Ն7%) (Ͻ53 and Ն53 mmol/mol)] are shown in Fig. 2 . Among persons with Hb A 1c Ն7% (Ն53 mmol/mol), persons with 1,5-AG Ͻ10 g/mL had substantially more retinopathy than those with 1,5-AG concentrations Ն10 g/mL (P Ͻ 0.001) ( Fig. 2A ). Among persons with Hb A 1c Ͻ7% (Ͻ53 mmol/mol), 1,5-AG categories did not provide significant additional risk stratification information (P value ϭ 0.10). A similar pattern was observed for the cumulative incidence of CKD (Fig. 2B) .
Conclusions
This study demonstrated strong associations between 1,5-AG and diabetic microvascular outcomes in a community-based setting and suggests that 1,5-AG has prognostic value in persons with diabetes and particularly those with Hb A 1c Ն7% (Ն53 mmol/mol). Low concentrations of 1,5-AG were strongly associated with prevalent retinopathy and incident CKD, particularly among those persons with diagnosed diabetes. In addition, 1,5-AG added significant information beyond Hb A 1c for discrimination of prevalent retinopathy. These results suggest that 1,5-AG may complement Hb A 1c for monitoring recent postprandial glycemic excursions in persons with diabetes, but additional studies are needed to establish its clinical utility. In persons without diabetes, the association of 1,5-AG with the development of diabetes and complications of diabetes was moderate to weak. Indeed, among persons without diabetes, the correlations of 1,5-AG with fasting glucose and Hb A 1c were very low. These findings are in contrast to those for other markers of hyperglycemia, such as glycated albumin and fructosamine, which are more strongly associated with Hb A 1c and fasting glucose (29 ) , and predict long-term outcomes even in persons without a diagnosis of diabetes (30 ) . There was no evidence of associations of 1,5-AG with long-term outcomes at values of approximately 15 g/mL or higher. This suggests that while low concentrations of 1,5-AG are relatively insensitive for the identification of early hyperglycemic states and future diabetes, they may be useful in the setting of overt diabetes. Our findings are consistent with the physiology of 1,5-AG, in which plasma concentrations of 1,5-AG are thought to show decreases only at the highest concentrations of blood glucose and reflect glucose excursions (31) (32) (33) .
1,5-AG has been shown in other studies to correlate with complications of diabetes. In a communitybased cross-sectional study of 517 persons with type 2 diabetes in Korea, low 1,5-AG concentrations were associated with both retinopathy and albuminuria (34 ) . We have previously shown cross-sectional associations of 1,5-AG with retinopathy and albuminuria in 1600 older adults in ARIC (mean age, 70 years) (35 ) . In one previous prospective study of approximately 2000 persons in Japan, 1,5-AG at baseline was significantly associated with incident cardiovascular events during 11 years of follow-up (36 ) . Our results extend the findings reported in this literature and suggest that 1,5-AG may be a useful biomarker of prognosis for microvascular outcomes in the setting of diabetes.
Nonetheless, certain limitations of our study should be considered in the interpretation of these data. These include the reliance on a single measurement of 1,5-AG, the limited number of fasting glucose and serum creatinine measurements during follow-up, and the fact that the retinal photographs were obtained only at visit 3 (in 1993-1994) , whereas measurements of 1,5-AG were obtained at baseline (in 1990 -1992). We were not able to validate the incident self-reported cases of diabetes identified after visit 4. Nonetheless, in sensitivity analyses of incident diabetes defined on the basis of a combination of glucose measurement, medication use, and self-reported information available for the first 6 years of follow-up, our results were similar. Strengths of this study include the large, community-based sample, the rigorous measurement of diabetes risk factors, and the long-term prospective follow-up with high retention (Ͼ90% contact rate during follow-up in ARIC).
In summary, this study demonstrated robust associations between low concentrations of 1,5-AG and microvascular complications in the setting of diabetes and supports a possible role for 1,5-AG as a useful biomarker of hyperglycemia. Additional studies are needed to fully evaluate the clinical utility of 1,5-AG in the setting of diabetes management.
